Special Issue

Ribosomal Antibiotics: Recent Advances

Message from the Guest Editor

The discovery and use of antibiotics have improved both longevity and quality of life. Ribosomal antibiotics comprise a major class of clinically available antibiotics, targeting more than a dozen different sites on both ribosomal subunits. This Issue welcomes manuscript submissions. Specifically, work from the following fields of research is especially encouraged:

- Resistance mechanisms of ribosomal antibiotics, including RNA modifications;
- Organic and enzymatic synthesis and modification of ribosomal antibiotics;
- In vitro and in situ structures of ribosomal antibiotics;
- Discovery of new ribosomal antibiotics using both classical natural products and bioinformatics approaches;
- Ribosomal antibiotics in producing bacteria;
- Pathogen specificity of ribosomal antibiotics;
- Ribosomal antibiotics in women's and children's health;
- Clinical studies of ribosomal antibiotics and nosocomial pathogens;
- Ribosomal antibiotics and their environmental impact;
- Ribosomal antibiotics use in animals;
- Ribosomal antibiotics in teaching and education.

Guest Editor

Dr. Miri Krupkin

Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA

Deadline for manuscript submissions

closed (31 March 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/129269

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI